Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 281 results for "Tecfidera Treated Patients"

Over Half of Audited Multiple Sclerosis Patients Currently Tre...

BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 month ago
[x]  

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

News Categories Clinical Trials Research News Industry Trends Agency
 Pharmscope4 weeks ago

TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERA is a first-line oral treatment for adults with ...
 MoneyShow.com2 weeks ago TECFIDERA(tm), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed  Finwin2 weeks ago British Columbia to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis  CEOWorld Magazine1 month ago
[x]  

Obamacare drug benefits block access to vital medicines

[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...
 World Socialist Web Site1 month ago

Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Introduction The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies.
 Pettinga Financial Advisors1 month ago
[x]  
Boston Globe

FDA okays Genzyme pill for Gaucher disease

Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...
 Boston Globe2 days ago
Boston Globe

FDA approves new injectable multiple sclerosis treatment from Cambridge's Biogen Idec

Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won US regulatory approval Friday to sell a new type of injectable drug that treats adults with the most common form of the ...
 Boston Globe6 days ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions  Jutia Group20 hours ago US FDA approves Biogen's MS drug  Bio Spectrum Asia2 days ago Biogen Idec finally gets approval for MS drug Plegridy  Examiner.com4 days ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 week ago
Motley Fool

Biogen Stock's Tecfidera Embarrasses Wall Street

It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...
 Motley Fool4 weeks ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera  FDA News1 month ago Biogen MS blockbuster Tecfidera earns high marks for safety  FiercePharma1 month ago

Price could be key for Sanofi's new Gaucher pill as it sets out against IV rivals

More than a couple of markets have been shaken up lately by new competition in oral form. Just take a look at Tecfidera in multiple sclerosis, Zytiga and Xtandi in prostate cancer, or Sovaldi, Gilead's ($GILD) hep C treatment that's put up ...
 FiercePharma1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less